ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX) Is Up 13.1% After Regeneron Tie-Up And FDA NDA Acceptance For TLX101-Px
In early April 2026, Telix Pharmaceuticals and Regeneron Pharmaceuticals announced a global 50/50 cost- and profit-sharing collaboration to co-develop next-generation radiopharmaceutical cancer therapies, alongside US$40 million upfront and the potential for up to US$2.10 billion in milestones and royalties to Telix.
Within days, the U.S. FDA accepted Telix’s resubmitted New Drug Application for its brain cancer imaging agent TLX101-Px (Pixclara), with Orphan Drug and Fast Track...